According to data published by 46brooklyn Research, a non-profit organization dedicated to drug pricing, it was revealed that by 2026 some Pharmaceutical companies will increase prices by up to 4% on at least 850 medications. According to the report, the beginning of the year was marked by higher prices for certain drugs, including the COVID-19 vaccine and Ozempic, despite pressure from the Executive Branch to make these medications more affordable for American consumers. The new costs were adjusted on January 9th. Despite the increases, AARP's prescription drug policy director, Leigh Purvis, pointed out that this is an annual measure and that these new prices are lower than those of a decade ago, when increases reached up to 10%. 

Purvis also emphasized that these list prices are not precisely what consumers usually pay at pharmacies or for prescriptions, as they are also determined by other factors such as discounts, insurance co-payments, reimbursements, deductibles, among others. For its part, the American pharmaceutical company, Pfizer, stated in a press release that "the modest increase is necessary to support investments that allow us to continue discovering and delivering new medicines, as well as address rising costs across the board." “Our business,” I stated. 

Despite the increases, federal efforts to prevent them continue, with the additional goal of helping those enrolled in programs like Medicare save up to 50% on their purchases; However, Diederik Stadig, a health and technology economist at ING Research, stated that "the agreements the Trump administration made with pharmaceutical companies do not change the fundamentals of the system. They are a temporary solution for a very small part of the market."